Offline dengan aplikasi Player FM !
Live from CCOLD: Dr Davids Discusses the ALPINE Trial in CLL
Manage episode 359431934 series 2812899
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.
Our Guest:
Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episode
Manage episode 359431934 series 2812899
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.
Our Guest:
Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
68 episode
Semua episode
×1 Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape 17:37
1 Highlights from EHA 2024 - Updates on the Treatment of CLL 42:13
1 LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL 16:33
1 Cutting Edge Advances in the Treatment of Lung Cancer 15:13
1 Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers 41:28
1 Immunotherapy for Kidney Transplant Patients with Skin Cancer 21:32
1 Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective 24:11
1 LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM 16:58
1 Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL 13:48
1 First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC 32:28
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table Discussion 26:41
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion 8:07
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment 14:52
1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs 10:38
Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.